MetaCap

Novartis AG (NVS)

NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

150.47-0.75 (-0.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$284.18B
Dividend yield
3.10% ($4.67)
Ex-dividend date
Mar 11, 2026
52-week range
126.50 – 170.46
Day range
150.24 – 152.70
Volume / Avg
2.24M / 2.18M
Beta
—

52-week range

$126.50$170.46

NVS stock today

Shares of Novartis (NVS) finished lower on Nov 20 at $150.47, a drop of 0.50% or $0.75 per share, versus the S&P 500's 3.70% decline. Shares are 11.7% below their 52-week high of $170.46, set on Feb 27, 2026 and 18.9% above the 52-week low of $126.50, in the middle of the past year's range. NVS is up 9.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.2%.

At 28.7x trailing earnings, Novartis trades in line with the peer-group median of 28.9x. Its forward P/E of 15.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Novartis pays an annual dividend of $4.67 per share, a 3.10% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Novartis

Company profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Vasant Narasimhan M.D.
Headquarters
Basel
Employees
75,267

Financial highlights

Full financials

Net income was $13.98 billion (+17.1% year over year). Diluted earnings per share came in at $7.15, up from $5.87.

Novartis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$13.98B$11.94B$14.85B$6.96B$24.02B
EPS (diluted)$7.15$5.87$7.10$3.17$10.63

Analyst forecast

Forecast

Consensus (11 analysts)

hold

Avg. price target

$157.10+4.41%

  • Strong buy 3
  • Buy 2
  • Hold 4
  • Sell 1
  • Strong sell 1

Target range

Low $130.00High $185.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$2.25 vs $2.25

Dividends

Dividend history
Annual dividend
$4.67
Last payment
$4.77
Ex-dividend date
Mar 11, 2026

NVS news

All NVS news

Novartis peers

Health Care sector
NVS peer companies
CompanyPrice% ChgMarket capCompare
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs NVS
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs NVS
ABTAbbott Laboratories103.00-0.84%$178.39Bvs NVS
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs NVS
PFEPfizer Inc.27.40-0.51%$156.18Bvs NVS
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs NVS
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs NVS
SNYSanofi ADS46.52+1.00%$111.70Bvs NVS

Indexes, lists and sector

Novartis stock FAQ

What is Novartis's stock price today?

NVS last traded at $150.47 as of Nov 20, 4:00 PM EST, down 0.50% on the day. Prices are delayed at least 15 minutes.

Does Novartis pay a dividend?

Yes. Novartis pays $4.67 per share annually, a 3.10% yield. The most recent dividend of $4.77 had an ex-dividend date of Mar 11, 2026.

What is NVS's P/E ratio?

NVS trades at a trailing P/E ratio of 28.72 and a forward P/E of 15.15, compared with a median of 28.9 for its closest peers.

Who is Novartis's CEO?

Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG, which has about 75,267 employees.

Has NVS ever split its stock?

Yes. The most recent NVS stock split was a 1116-for-1000 split on Apr 9, 2019, one of 2 splits on record.

What is the NVS 52-week high?

The 52-week high for NVS is $170.46 and the 52-week low is $126.50. The stock is currently 11.7% below its high.

Compare NVS